Related Experiment Video
Updated: May 7, 2026

Customization of Aspergillus niger Morphology Through Addition of Talc Micro Particles
Published on: March 15, 2012
Biotransformation of 20(S)-protopanaxadiol by Aspergillus niger AS 3.1858
Guangtong Chen1, Xue Yang1, Jianlin Li1
1School of Medicine, Nantong University, 19 Qi Xiu Road, Nantong 226001, PR China.
Abstract:
The biotransformation of 20(S)-protopanaxadiol (1) by Aspergillus niger AS 3.1858 was conducted. Seven metabolites 26-hydroxyl-20(S)-protopanaxadiol (2); 23, 24-en-25-hydroxyl-20(S)-protopanaxadiol (3); 25, 26-en-20(S)-protopanaxadiol (4); (E)-20, 22-en-25-hydroxyl-20(S)-protopanaxadiol (5); 25, 26-en-24(R)-hydroxyl-20(S)-protopanaxadiol (6); 25, 26-en-24(S)-hydroxyl-20(S)-protopanaxadiol (7); and 23, 24-en-25-ethoxyl-20(S)-protopanaxadiol (8) were afforded. Among them, 6, 7, and 8 are new compounds. The chemical structures of these metabolites were elucidated based on extensive spectral data including 2D NMR and HRMS. In addition, the cytotoxicity of substrate and all transformed products was evaluated by MTT assay using a panel of seven human tumor cell lines (Du-145, Hela, K562, K562/ADR, SH-SY5Y, HepG2, and MCF-7 cells) and one normal cell line Vero.
Related Concept Videos
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
